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Abstract The GLP-1 receptor (GLP-1R) mediates the insuli-
notropic effects of the incretion hormone glucagon-like peptide 1
(7^36) amide (GLP-1). Recently, we cloned the 5P-flanking
region of the human GLP-1R gene. To characterize tissue- and
cell-specific cis-regulatory elements, we constructed a series of
5P-deletions of the promoter. The activity of these constructs was
tested in different cell lines. An element with high homology to
PS1 was found to repress GLP-1R promoter activity in
fibroblasts and pancreatic D-cells, but was not active in
pancreatic A- and B-cells. PS1 was described to inhibit activation
of a D-cell-specific enhancer. Cloning the PS1-like element
upstream a heterologous promoter (SV40) revealed that it is
functionally active independently from this enhancer. Our data
suggest that basal activity of the GLP-1R promoter is silenced in
a tissue- and cell-specific manner by negatively acting cis-
regulatory elements, including a PS1-like element.
z 1998 Federation of European Biochemical Societies.
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1. Introduction
Glucagon-like peptide 1 (7^36) amide (GLP-1) arises as a
post-translational product of proglucagon processing in intes-
tinal cells and plays an important physiological role in the
regulation of insulin secretion and proinsulin gene expression
(for review see [1,2]). Its action is mediated by a stimulatory
G-protein coupled receptor (GLP-1R) at the pancreatic L-cell,
connected to the adenylate cyclase pathway in a glucose-de-
pendent manner [3^6]. The GLP-1R is expressed in a cell- and
tissue-speci¢c manner in rat islets [7], rat lung [8], mouse small
and large intestine, liver and kidney [9], human insulinoma
[10], human islets [11,12], a human gastric tumor cell line
[13] and human brain and heart [14]. It belongs to the family
of seven transmembrane-spanning receptors that include se-
cretin [15], parathyroid hormone [16], calcitonin [17] and glu-
cagon receptors [18,19].
It is of special interest to study the cell- and tissue-speci¢c
expression of the GLP-1R since it is the target for a new
therapeutic approach in diabetes mellitus type 2 [20^22].
Moreover, it could be shown that GLP-1R levels signi¢cantly
in£uence glucose-mediated insulin release [23] and, therefore,
knowledge would be valuable about the regulation of the
GLP-1R gene. For this purpose we cloned the 5P-£anking
sequences of the human GLP-1R gene ([24], accession No.
U66062). Sequence analysis of this region revealed no
TATA- or CAAT-box motif, but several other putative cis-
regulatory elements, including three Sp1 binding sites, two of
them activating gene transcription [25]. Sp1 is a well-known
ubiquitous transcription factor [26,27] and seems to facilitate
constitutive basal expression. Therefore, activation of gene
transcription by Sp1 cannot be mainly responsible for cell-
and tissue-speci¢city. There is evidence for the existence of
additional regulatory elements in the GLP-1R promoter in-
volved in negative control of transcription [24]. A candidate
for one of these silencers in the GLP-1R promoter is an ele-
ment in the region from 3961 to 3978, which is homologous
to a recently characterized cis-regulatory element in the soma-
tostatin gene (PS1) [28]. PS1 is located between 3220 and
3237 and decreases somatostatin gene promoter activity
stimulated by a pancreatic D-cell-speci¢c enhancer (SMS-
UE) in an islet D-cell line and in ¢broblasts, but not in an
islet B-cell line [28]. The silencing activity of PS1 is not de-
pendent on the position relative to SMS-UE. It was proposed
that PS1 is involved in preventing somatostatin gene expres-
sion in non-islet cells. No data are available, demonstrating
that PS1 exerts repressing functions independently from SMS-
UE. Sequence analysis of the GLP-1R 5P-£anking region re-
vealed no comparable enhancer. Therefore, it was the aim of
this study to elucidate the role of the PS1-like element inde-
pendently from SMS-UE and in the regulation of GLP-1R
expression.
2. Materials and methods
2.1. Plasmid construction
A DNA fragment containing the GLP-1 receptor promoter ranging
from 31632 to +37 cloned into the NheI and BglII sites of the pGL
basic luciferase vector (Promega, Madison, USA) was used as tem-
plate (T). 5P-Deletions were constructed using the erase-a-base system
(Promega, Madison, USA) according to the suppliers protocol.
Clones were analyzed by dideoxy chain termination sequencing (Se-
quenase, USB, Amersham, Cleveland, USA). Promoter fragments
ranging from 31010 to +37 (containing the PS1-like element) and
from 3916 to +37 (missing the PS1-like element) were used for tran-
sient transfections.
E¡ects of PS1 and mutated PS1 (PS1M) in a heterologous promoter
were studied by annealing complementary oligonucleotides (MWG
Biotech, Ebersberg, Germany) with appropriate ends (coding strand:
CTA GCT GGC ATC AAG GTT CTT TGG TGG GGA for PS1;
CTA GCT GGC ATC GCG GGC CTT TGG TGG GGA for PS1M.
Essential nucleotides for activity and mutated nucleotides are printed
in bold). The resulting double strands were ligated into pGL promoter
luciferase vector, digested with NheI and BglII. Insertion of oligonu-
cleotides was veri¢ed by dideoxy chain termination sequencing.
2.2. Transient transfections
The di¡erent promoter reporter gene constructs were transiently
cotransfected with pSV-L-Gal vector (Promega, Madison, USA) into
four cell lines (hamster insulinoma tumor cells, pancreatic B-cell line
HIT; hamster glucagonoma cells, pancreatic A-cell line INR1G9; rat
insulinoma tumor cells, pancreatic D-cell line RIN-1027-B2 and Chi-
nese hamster lung ¢broblasts, CHL) using DEAE-dextran or the Per-
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Fect Lipid method (Pfx-3) according to the suppliers protocol (Invi-
trogen, San Diego, USA). After transfection cells were plated into 35
mm dishes and incubated for 24 to 48 h in appropriate media (HIT:
RPMI 1640/L-glutamine, 10% FCS, 5% horse serum, 100 U/ml pen-
icillin, and 100 Wg/ml streptomycin; INR1G9 and RIN-1027-B2:
RPMI 1640/L-glutamine, 10% FCS, 100 U/ml penicillin, and 100 Wg/
ml streptomycin; CHL: RPMI 1640/L-glutamine, 10% FCS, 1 mM
sodium pyruvate, 1Unon-essential amino acids, 100 U/ml penicillin
and 100 Wg/ml streptomycin). All media and supplements were from
GIBCO, BRL, Eggenstein, Germany). Cells were lyzed and L-galac-
tosidase and luciferase activity was determined by chemoluminescense
in a luminometer (Lumat LB 9501, Berthold, Bad Wildbad, Germany)
using the appropriate substrates (Tropix, Bedford, USA). Cell lysates
for L-galactosidase measurements were ¢rst incubated for 50 min at
48‡C to inactivate endogenous L-galactosidase. All measurements
were taken in duplicate and from at least ¢ve independent transfec-
tions. Luciferase activity levels, normalized with L-galactosidase activ-
ities are expressed as percent of control.
2.3. Nuclear extracts and DNase I protection experiments
Nuclear extracts from CHL, HIT, RIN-1027-B2 and INR1G9 cells
were prepared according to Dignam et al. [29]. A 196 bp DNA frag-
ment ranging from 31039 (SalI) to 3843 (PstI) was isolated from
plasmid T, radioactively endlabeled using T4 polynucleotide kinase
and digested with Van91I (3877) to create a 162 bp fragment with
a single radioactive label. For DNase protection the probe was mixed
with 40 and 80 Wg of nuclear extracts or BSA and treated according to
the suppliers protocol (Core Footprinting System, Promega). G and
G+A sequencing reactions were performed as described by Maxam
and Gilbert [30]. The DNA fragments were resolved on a 6% denatur-
ing polyacrylamide gel.
2.4. Electrophoretic mobility shift assay (EMSA)
A double stranded oligonucleotide PS1 (which was also used for
cloning) was radioactively endlabeled using T4 polynucleotide kinase.
Binding reactions with nuclear extracts from HIT, CHL, RIN-1027-
B2 and INR1G9 cells were performed according to the suppliers pro-
tocol at room temperature (Gel Shift Assay System, Promega) for
30 min in the presence of 2 Wg poly(dIdC). Competitors were present
in 50- or 500-fold excess. Complexes were separated on a non-dena-
turing 4% polyacrylamide gel. For in-situ DNA-protein UV-crosslink-
ing gels were exposed to UV light (312 nm) for 5 to 10 min. After
exposure to X-ray ¢lms, gel slices were cut out and transferred to
denaturing SDS polyacrylamide gels [31]. After electrophoresis the
gels were dried and exposed. Molecular weights of the proteins are
determined by comparison to pre-stained protein standards (BioRad,
Hercules, USA).
3. Results
3.1. Analysis of the tissue- and cell-speci¢c activity of the
human GLP-1R promoter by 5P-deletions
5P-Deletions of the human GLP-1R promoter and subse-
quent transient transfections of the constructs into HIT (pan-
creatic B-cell line, GLP-1R producing), InR1G9 and CHL
cells (pancreatic A-cell line and ¢broblasts, both GLP-1R
non-producing cells) revealed that, by deletion to 31630,
cell-speci¢city for pancreatic A- and B-cells is lost and that
in the region from 31630 to 3565 a tissue-speci¢c silencer
element is located [24]. Computer analysis of the sequence
revealed an element from 3978 to 3961 with a high homol-
ogy to PS1 (Fig. 1A). The essential nucleotides are completely
conserved. To clarify the role of this PS1-like element, we
constructed a series of 5P-deletions in the region from
31630 to 3916 of the promoter upstream of a luciferase
reporter gene. Activity of each construct was measured by
transient transfections into di¡erent GLP-1R producing and
non-producing cell lines. For comparison with published data,
a pancreatic D-cell line (RIN-1027-B2) was included in the
transfection experiments. 5P-Deletion from 31010 (contains
the PS1-like element) to 3916 (lacking the PS1-like element)
(Fig. 1B) showed an increase in promoter activity in D-cells
and ¢broblasts, but no e¡ects in B-cells (Fig. 2). These results
are in good accordance to the published data for PS1 [28]. In
the pancreatic A-cell line InR1G9 no e¡ect can be observed
by deletion of 94 bp containing the PS1-like element. These
data suggest that the PS1-like element is involved in the tissue-
and cell-speci¢c expression of the human GLP-1R.
3.2. Activity of the PS1-like element independently from
SMS-UE
In the somatostatin gene promoter PS1 represses the activ-
ity of a D-cell-speci¢c enhancer (SMS-UE). The sequence of
the GLP-1R promoter revealed no comparable enhancer, but
the functionality of the PS1-like element seems likely. To eval-
uate, if it can function independently from SMS-UE, we
cloned a 30 bp oligonucleotide containing the PS1-like ele-
ment upstream a heterologous promoter (pGL promoter, lu-
ciferase gene under the control of an SV40 promoter, PS1). As
a negative control another plasmid was constructed, contain-
ing a 30 bp oligonucleotide with mutated essential nucleotides
of the PS1-like element (PS1M). Each construct was tested for
promoter activity by transient transfections into di¡erent cell
lines in comparison to the SV40 promoter (Prom) (Fig. 3).
The PS1-like element repressed the activity of the SV40 pro-
moter by about 40% in ¢broblasts (CHL) and D-cells (RIN-
1027-B2), but had no e¡ects in A- (InR1G9) and B-cells
(HIT). These data are in accordance with results obtained
with 5P-deletions of the GLP-1R promoter. Cloning of the
mutated PS1-like sequence did not alter the activity of the
SV40 promoter in all four cell lines. Therefore, the PS1-like
element can apparently act independently from SMS-UE and
confers to cell- and tissue-speci¢c expression of the human
GLP-1R gene.
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Fig. 1. A: Sequence homology between PS1 from the somatostatin
gene and the PS1-like element found in the 5P-£anking region of the
human GLP-1R gene. Asterics indicate essential nucleotides for ac-
tivity, which are completely conserved in the GLP-1R gene. B: Par-
tial sequence of the 5P-£anking region of the human GLP-1R gene.
Numbers indicate the positions in relation to the main transcription
start site, the arrows show the deletion constructs used for transient
transfections. Bold capital letters represent the PS1-like element.
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3.3. DNase footprint and electrophoretic mobility shift analysis
DNase footprint and electrophoretic mobility shift analysis
was used to prove binding of nuclear proteins to the PS1-like
sequence. With nuclear extracts of CHL cells, a protection in
the region of the PS1-like element was seen (Fig. 4). Similar
results were obtained with nuclear proteins of the other three
cell lines (data not shown). To further characterize the pro-
teins binding to the PS1-like sequence, nuclear extracts from
all four cell lines were incubated with the endlabeled oligonu-
cleotide containing the PS1-like sequence for electrophoretic
mobility shift analysis. DNA-protein complexes were resolved
on a 4% non-denaturing polyacrylamide gel. With all four
nuclear extracts two retarded bands were found (S1 and S2),
although in di¡erent intensities (Fig. 5). In CHL and RIN-
1027-B2 cells the slower migrating signal S1 is more promi-
nent, whereas the faster band S2 is more intense than S1 in
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Fig. 3. Transient transfections of four di¡erent cell lines with PS1
(PS1) and PS1M (PS1M) cloned upstream an SV40 promoter, di-
recting luciferase expression as described in Section 2. The control
vector pGL2 promoter (Prom) was set to 100%. PS1 clearly de-
creases promoter activity in CHL (¢broblasts) and RIN-1027-B2
(D-cells) to about 60% of control. The mutated sequence PS1M has
no in£uence on promoter activity in all four cell lines. Luciferase
activity was normalized by cotransfection with L-galactosidase. Re-
sults represent values from eight independent transfections along
with the standard deviation.
Fig. 4. DNase footprint analysis with nuclear extracts from CHL
cells. The DNA fragment, containing the PS1-like element, was in-
cubated with 60 Wg BSA (lane B) or with 40 Wg (lane C1) and 80
Wg (lane C2) nuclear proteins from CHL cells, partially digested
with DNase I and resolved on a denaturing 6% gel as described in
Section 2. Sequencing reactions of the fragment were run in parallel
on the gel (lanes G/A and G). The protected region is indicated
with the sequence of the PS1-like element.
Fig. 2. Transient transfections of four cell lines with three 5P-deletion constructs of the GLP-1R promoter (schematic representation on the left
side) as described in Section 2. The arrows indicate the position of the PS1-like element. The promoter/reporter gene construct missing the
PS1-like element was set to 100%. Whereas no signi¢cant change in promoter activity occurred by deletion of the PS1-like element in HIT
(B-cell line) and InR1G9 (A-cell line), a clear increase is observed in RIN-1027-B2 (D-cell line) and CHL (¢broblasts). The asterics indicate a
P-value9 0.015 in comparison to P-916. Luciferase activity was normalized by cotransfection with L-galactosidase. Results represent values
from six independent transfections along with the standard deviation.
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InR1G9 and HIT cells. Both signals can be competed by
addition of an excess of PS1-like oligonucleotide and to a
lesser extent by an excess of PS1M oligonucleotide. These
data point to a functional DNA-protein complex in ¢bro-
blasts and D-cells present in band S1.
3.4. In-situ DNA-protein UV-crosslinking
To characterize the proteins binding to the PS1-like oligo-
nucleotide, DNA-protein complexes S1 and S2 were cova-
lently linked with UV light in native gels. After exposure
the gel slices were cut out and transferred to a denaturing
SDS gel. Analysis of complex S1 revealed that with nuclear
extracts from all four cell lines two proteins with a molecular
weight of 120 and 95 kDa bind to the oligonucleotide (Fig. 6).
Although the amounts of nuclear proteins and radioactively
labeled oligonucleotide are the same during all binding reac-
tions, the intensity of the 95 kDa proteins is clearly higher in
CHL and RIN-1027-B2 cells than in cells which show no
e¡ect of the PS1-like sequence. Therefore, the 95 kDa protein
probably mediates the repression of gene transcription. With
band S2 similar results are obtained: two nuclear proteins
from all four cell lines bind to the DNA with a molecular
weight of 110 and 65 kDa, but there is no di¡erence in the
intensity.
4. Discussion
In the region from 31630 to 3565 of the 5P-£anking se-
quence of the human GLP-1R gene, a tissue-speci¢c, nega-
tively acting cis-regulatory element is apparently located, as
shown by transient transfections of ¢broblasts with di¡erent
5P-deletion constructs [24]. With computer analysis a sequence
was found, exhibiting high homology to the earlier character-
ized silencer PS1 [28]. Since PS1 represses the activity of a D-
cell-speci¢c enhancer (SMS-UE) of the somatostatin gene in
¢broblasts and shows no e¡ect in B-cells, it seems a possible
candidate for the tissue-speci¢c regulation of the GLP-1R
gene expression. No sequence was found in the 5P-£anking
region of the human GLP-1R gene comparable to SMS-UE,
therefore, PS1 should be functionally active independently
from SMS-UE. The ¢rst hints for functionality of the PS1-
like element were promoter activities in transient transfections
of di¡erent 5P-deletion constructs of the human GLP-1R pro-
moter. Removing the PS1-like sequence by deletion from
31010 to 3916 lead to a clear increase of promoter activity
in ¢broblasts and islet D-cells and no e¡ect in islet B-cells.
These results are in accordance with earlier published data
from Vallejo et al. [28]. In islet A-cells no repression by the
PS1-like sequence could be observed. A basal transcription of
the human GLP-1R gene is repressed in a cell- and tissue-
speci¢c manner by the PS1-like element.
To prove functionality of the PS1-like element independ-
ently from SMS-UE, a double stranded oligonucleotide con-
taining the PS1-like sequence was cloned upstream an SV40
promoter of a luciferase expression vector (PS1). As a nega-
tive control a plasmid served containing a mutated and there-
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Fig. 5. Electrophoretic mobility shift analysis of an oligonucleotide
containing the PS1-like sequence as described in Section 2. Lanes 1
in each panel show the free oligonucleotide, in lanes 2 nuclear ex-
tracts of the above indicated cell line were added, the following
lanes show the competition with increasing amounts of unlabeled
PS1 or PS1M oligonucleotide (50- and 500-fold excess). Retarded
DNA-protein complexes are indicated by arrows S1 and S2, the free
oligonucleotide by F. Band S1 is clearly more prominent in CHL
and RIN-1027-B2 cells in comparison to S2 than in HIT and
InR1G9 cells.
Fig. 6. In-situ DNA-protein UV-crosslinking of band S1 and S2
with nuclear proteins from four di¡erent cell lines as described in
Section 2. Lane R: RIN-1027-B2 cells, lane C: CHL cells, lane H:
HIT cells, lane I: InR1G9 cells. Lane F indicates the free oligonu-
cleotide, arrows at the right side the protein markers with the mo-
lecular weight in kDa. With all four nuclear extracts proteins of the
same molecular weight were linked to the radioactively labeled oli-
gonucleotide for S1 (120 and 95 kDa) and S2 (110 and 65 kDa).
The 95 kDa protein is more prominent in CHL and RIN-1027-B2
cells (large arrow on the left side).
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fore inactivated form of PS1 (PS1M). Transient transfections
of di¡erent cell lines with these constructs clearly revealed a
40% reduction of gene expression in pancreatic D-cells and
¢broblasts and no e¡ect in pancreatic B- and A-cells. The
mutated PS1-like sequence did not in£uence promoter activity
in all cell lines. Therefore, it was shown that the PS1-like
sequence resembles a cis-regulatory element, which can repress
transcription independently from a D-cell-speci¢c enhancer
and in a cell- and tissue-speci¢c manner.
To characterize the proteins, which can interact with the
PS1-like element, we performed DNase footprint analysis
and found a protection centered around the PS1-like element.
Electrophoretic mobility shift analysis with nuclear extracts
from all four cell lines revealed two retarded DNA-protein
complexes. However, the slower migrating complex S1 was
more intense in pancreatic D-cells and ¢broblasts. UV-cross-
linking experiments revealed that there was no di¡erence in
proteins binding to the PS1-like sequence with all four nuclear
extracts for complex S2, but in complex S1 a 95 kDa protein
was more prominent in D-cells and ¢broblasts, putatively re-
sembling the functional transcription factor. The same pro-
teins from complex S1 and S2 can also bind to the mutated
oligonucleotide PS1M including the 95 kDa protein (data not
shown). Possibly, a conformational change of the protein
structure is necessary for functional activity. Still, it cannot
be excluded that all proteins found are in vitro artefacts and
that the functional transcription factor can only bind in vivo
or is masked by unspeci¢c proteins.
PS1 was ¢rst characterized as a repressor of somatostatin
gene expression in ¢broblasts and islet D-cells [28]. The pub-
lished in vivo data are in accordance with our results concern-
ing repression of gene transcription in di¡erent cell lines, but
the in vitro data of proteins binding to PS1 are di¡erent.
Vallejo et al. [28] identi¢ed two proteins of 120 and 130
kDa by UV-crosslinking in ¢broblasts, an additional protein
of 100 kDa in islet B-cells and several more small proteins
with a molecular weight between 40 and 45 kDa in D-cells.
We found proteins of 120 and 95 kDa in all four cell lines
linked to the oligonucleotide, although the protein of 95 kDa
was more prominent in ¢broblasts and D-cells. These di¡er-
ences may be due to the di¡erent cell lines used or to the
substitution of dTTP by Br-dUTP. Br-dUTP leads to a
more e⁄cient UV-crosslinking of proteins to DNA, but we
worked without this substitution to be as close as possible to
the in vivo situation. Another di¡erence maybe due to the
sequence of the used oligonucleotides, which have a high ho-
mology, but are not identical and, therefore, can give rise to
another binding speci¢city.
Silencer elements are important regulators of cell-speci¢c
expression of a number of genes. For example, neuron-speci¢c
expression of SCG10 [32,33] and type II Na channel [34]
appears to be due to selective repression and de-repression
and activation by non-cell-speci¢c enhancers. Both PS1 and
the PS1-like element bind to ubiquitously distributed nuclear
proteins, and the availability of the proteins seems to deter-
mine the repressing action of the PS1-like element. They do
not act as absolute repressors, which are functionally active
independently from other factors [35], but rather interact with
other regulatory elements. The e¡ect of PS1 on the somato-
statin gene expression is compensated in part by a D-cell-
speci¢c enhancer and the PS1-like element is not able to re-
press the activity of the GLP-1R promoter completely. Similar
mechanisms are found for the regulation of the genes coding
for lysozyme [36] and prolactin [37]. The interaction of pos-
itively and negatively acting factors de¢nes the pattern of gene
expression in di¡erent cell types [38^42]. PS1 might be devel-
opmentally regulated and be involved in determining tran-
scription of di¡erent genes during pancreatic islet cell matura-
tion, since it does not repress gene expression in A- and B-
cells. The sequential appearance of hormones in pre-B-cells
and later in mature cells points to a di¡erentiation of ¢rst
A- and B-cells and then later of D-cells [43].
Repression of gene transcription seems to be an important
regulatory mechanism in the islet cell-speci¢c gene expression
during pancreatic development. Insulin [44,39] and gastrin [38]
transcription, for example, is directed by silencers in interac-
tion with positive regulatory elements. A similar situation is
found for the expression of the human GLP-1R. Transcrip-
tion of the gene is under the control of di¡erent, cell-speci¢c
silencers like PS1 and ubiquitous enhancers like Sp1, which
interact to enable the tissue- and cell-type-speci¢c transcrip-
tion of the gene.
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